-
摘要:目的
探讨足细胞标记蛋白（Podocalyxin）在乳腺导管内癌（DCIS）及浸润性导管癌（IDC）中的表达差异及与临床病理学特征及预后的关系。
方法随机抽取62例DCIS样本（低/中级别DCIS 33例，高级别29例），129例IDC样本，采用免疫组织化学SP法检测两种样本中Podocalyxin的表达。
结果在DCIS和IDC中Podocalyxin阳性率分别为35.48%（22/62）和51.94%（67/129），两者差异有统计学意义（P < 0.05）。DCIS中，低/中级别DCIS的Podocalyxin阳性率明显低于高级别（P < 0.05）。IDC中Podocalyxin阳性表达在肿瘤分级、pTNM肿瘤分期和淋巴结转移中差异有统计学意义（P < 0.05）。Kaplan-Meier单因素生存分析显示IDC中Podocalyxin阳性表达等多个因素和IDC患者无瘤生存期的影响具有统计学意义。Cox多因素分析表明Podocalyxin阳性和淋巴结转移是影响预后的独立危险因素。
结论Podocalyxin在IDC中表达明显高于DCIS，提示其在乳腺癌的发展及浸润机制中可能发挥重要作用；在IDC中podocalyxin阳性表达与较差的预后密切相关。
Abstract:ObjectiveTo discuss the difference in podocalyxin expression between ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC), and their relationships with clinicopathological parameters and prognosis of breast cancer.
MethodsImmunohistochemical SP method was applied to detect the expression and location of podocalyxin in the breast tissues of 62 DCIS (33 cases of low/intermediate grade and 29 cases of high grade) and 129 IDC samples.
ResultsThe expression of podocalyxin in DCIS and IDC were 35.48% (22/62) and 51.94% (67/129) (P < 0.05). It was preferentially expressed in high-grade DCIS, compared with low/intermediate-grade DCIS (P < 0.05). Podocalyxin expression in IDC was associated with tumor grade, pTNM stage and lymph node metastasis in IDC (P < 0.05). Kaplan-Meier univariate analysis revealed positive podocalyxin expression and other factors had significance for disease free survival. Cox model analysis revealed positive podocalyxin expression and lymph nodes metastasis were dangerous independent prognosis factor for IDC.
ConclusionPodocalyxin expression is significantly higher in IDC than that in DCIS. Podocalyxin could be an important index for the development and invasive of breast cancer. In IDC patients, podocalyxin positive expression is closely associated with poor prognosis.
-
Key words:
- Breast cancer /
- Podocalyxin /
- Immunohistochemistry /
- Prognosis
-
-
![]()
图 1 Podocalyxin在正常乳腺组织、DCIS和IDC中的表达 (IHC)
Figure 1 Podocalyxin expression in normal breast tissues, DCIS and IDC tissues (IHC)
![]()
图 2 129例IDC中Podocalyxin表达的总生存曲线
Figure 2 Overall survival curves of podocalyxin expression in 129 IDC patients
![]()
图 3 129例IDC中podocalyxin阳性与阴性表达的无瘤生存曲线
Figure 3 Disease-free survival curves of 129 IDC patients with positive and negative podocalyxin expression
表 2 乳腺IDC中Podocalyxin的表达及与临床病理参数的关系
Table 2 Relationship between podocalyxin expression and clinicopathologic index in IDC patients
下载: 导出CSV
表 3 Cox多因素回归分析IDC临床病理参数与生存的关系
Table 3 Cox multivariate regression analysis of clinicopathological parameters and survival of IDC patients
下载: 导出CSV
-
[1] Nielsen JS, McNagny KM. The role of podocalyxin in health and disease[J]. J AM Soc Nephrol, 2009, 20(8): 1669-76. doi: 10.1681/ASN.2008070782
[2] 唐平, 魏兵, 杨雯娟, 等.乳腺癌预后/预测因子[J].中华病理学杂志, 2011, 40(2): 73-6. http://cdmd.cnki.com.cn/Article/CDMD-10422-1015379920.htm Tang P, Wei B, Yang WJ, et al. Prognostic factors of breast cancer[J]. Zhonghua Bing Li Xue Za Zhi, 2011, 40(2): 73-6. http://cdmd.cnki.com.cn/Article/CDMD-10422-1015379920.htm
[3] Ellis IO, Collins L, Ichihara S, et al. Invasive carcinoma of no special type[M]//Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast. Lyon: IARC Press, 2012: 33-8.
[4] Somasiri A, Nielsen JS, Makretsov N, et al. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression[J]. Cancer Res, 2004, 64(15): 5068-73. doi: 10.1158/0008-5472.CAN-04-0240
[5] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-917. doi: 10.1002/ijc.v127:12
[6] 张敏璐, 黄哲宙, 郑莹.中国2008年女性乳腺癌发病、死亡和患病情况的估计及预测[J].中华流行病学杂志, 2012, 33(10): 1049-51. doi: 10.3760/cma.j.issn.0254-6450.2012.10.012 Zhang ML, Huang ZZ, Zheng Y. Estimates and prediction on incidence, mortality and prevalence of breast cancer in China, 2008[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2012, 33(10): 1049-51. doi: 10.3760/cma.j.issn.0254-6450.2012.10.012
[7] Orlando RA, Takeda T, Zak B, et al. The glomerular epithelial cell anti-adhesin podocalyxin associates with the actin cytoskeleton through interactions with ezrin[J]. Am J Soc Nephrol, 2001, 12(8): 1589-98. https://www.researchgate.net/publication/11880021_The_glomerular_epithelial_cell_anti-adhesin_podocalyxin_associates_with_the_actin_cytoskeleton_through_interactions_with_ezrin
[8] Li Y, Li J, Straight SW, et al. PDZ domain-mediated interaction of rabbit podocalyxin and Na (+)/H (+) exchange regulatory factor-2[J]. Am J Physiol Renal Physiol, 2002, 282(6): 1129-39. doi: 10.1152/ajprenal.00131.2001
[9] Strilić B, Kucera T, Eglinger J, et al. The molecular basis of vascular lumen formation in the developing mouse aorta[J]. Dev Cell, 2009, 17(4): 505-15. doi: 10.1016/j.devcel.2009.08.011
[10] Snyder KA, Hughes MR, Hedberg B, et al. Podocalyxin enhance breast tumor growth and metastasis and is a target for monoclonal antibody therapy[J]. Breast Cancer Res, 2015, 17: 46. doi: 10.1186/s13058-015-0562-7
[11] Sizemore S, Cicek M, Sizemore N, et al. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin[J]. Cancer Res, 2007, 67(13): 6183-91. doi: 10.1158/0008-5472.CAN-06-3575
[12] Boman K, Larsson AH, Segersten U, et al. Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer[J]. Br J Cancer, 2013, 108(11): 2321-8. doi: 10.1038/bjc.2013.215
[13] Laitinen A, Böckelman C, Hagström J, et al. Podocalyxin as a prognostic marker in gastric cancer[J]. PloS One, 2015, 10(12): e0145079. doi: 10.1371/journal.pone.0145079
[14] Larsson A, Johansson ME, Wangefjord S, et al. Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer[J]. Br J Cancer, 2011, 105(5): 666-72. doi: 10.1038/bjc.2011.295
[15] Koch LK, Zhou H, Ellinger J, et al. Stem cell marker expression in small cell lung carcinoma and developing lung tissue[J]. Hum Pathol, 2008, 39(11): 1597-605. doi: 10.1016/j.humpath.2008.03.008
[16] Lin CW, Sun MS, Liao MY, et al. Podocalyxin-like 1 promotes invadopodia formation and metastasis through activation of Rac1/Cdc42/cortactin signaling in breast cancer cells[J]. Carcinoqenesis, 2014, 35(11): 2425-35. doi: 10.1093/carcin/bgu139
[17] Meng X, Ezzati P, Wilkins JA. Requirement of podocalyxin in TGF-Beta induced epithelial mesenchymal transition[J]. PLoS One, 2011, 6(4): e18715. doi: 10.1371/journal.pone.0018715
[18] Nielsen JS, Graves ML, Chelliah S, et al. The CD34-related molecule podocalyxin is a potent inducer of microvillus formation[J]. PLoS One, 2007, 2(2): e237. doi: 10.1371/journal.pone.0000237
[19] Graves ML, Cipollone JA, Austin P, et al. The cell surface mucin podocalyxin regulates collective breast tumor budding[J]. Breast Cancer Res, 2016, 18(1): 11. doi: 10.1186/s13058-015-0670-4
[20] 张荣菊, 牛昀, 高玉霞.乳腺导管原位癌浸润机制的研究进展[J].中华病理学杂志, 2009, 38(1): 63-5. http://youxian.cnki.com.cn/yxdetail.aspx?filename=YYCD2017030600E&dbname=CAPJ2015 Zhang RJ, Niu Y, Gao YX. Recent advances in studies on in-situ and invasive ductal carcinoma[J]. Zhonghua Bing Li Xue Za Zhi, 2009, 38(1): 63-5. http://youxian.cnki.com.cn/yxdetail.aspx?filename=YYCD2017030600E&dbname=CAPJ2015
[21] 王舒, 倪青.钼靶、彩超及磁共振在乳腺导管原位癌中的诊断价值[J].肿瘤防治研究, 2015, 42(6): 597-600. doi: 10.3971/j.issn.1000-8578.2015.06.014 Wang S, Ni Q. Accuracy of mammography, color doppler ultrasonography and magnetic resonance imaging in predicting puctal carcinoma in situ[J]. Zhong Liu Fang Zhi Yan Jiu, 2015, 42(6): 597-600. doi: 10.3971/j.issn.1000-8578.2015.06.014
计量
- 文章访问数: 1167
- HTML全文浏览量: 368
- PDF下载量: 286
